Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

2,000 people have been recruited into the world’s largest clinical trial to test the clinical and cost effectiveness of the controversial flu drug oseltamivir (Tamiflu) in primary care. The trial aims to clear up the widespread uncertainty over whether people with flu symptoms should be treated with antiviral drugs in the community.

Should flu symptoms be treated with antivirals in primary care.jpg

Led in the UK by researchers in Oxford University’s Nuffield Department of Primary Care Health Sciences, the ALIC4E trial investigates whether oseltamivir is cost effective and beneficial to patients consulting their General Practitioner with flu symptoms. In particular, it will understand if older people, infants, people with other health conditions, those treated early, or those with particularly severe flu can benefit from the treatment.

Find out more (Nuffield Department of Primary Care Health Sciences website)